Home Blog of Signal Transduction Immunology & Inflammation SPHK

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

SPHK

Host-Erythrocytic Sphingosine-1-Phosphate Regulates Plasmodium Histone Deacetylase Activity and Exhibits Epigenetic Control over Cell Death and Differentiation

164 views | May 28 2023

The study suggests that altering host S1P levels could dysregulate PfHDAC-1 activity and modulate the transcriptional patterns of genes associated with malaria parasite proliferation and virulence, offering a novel approach to combat malaria resistance to conventional antimalarial drugs. [Read the Full Post]

Technique-Dependent Relationship between Local Ski Bending Curvature, Roll Angle and Radial Force in Alpine Skiing

161 views | May 28 2023

This study analyzed the interplay between ski and snow in skiing technique and performance using a PyzoFlex® ski prototype to measure local ski curvature and found that segmental w″ differed temporally and segmentally depending on the employed technique and turn phase. [Read the Full Post]

Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma

63 views | May 27 2023

The study found that SK2 downregulation or inhibition induces mitophagy and apoptosis in multiple myeloma cell lines through the SET/PP2AC/PARK2 pathway, suggesting potential therapeutic strategies for the disease. [Read the Full Post]

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

72 views | May 27 2023

The study demonstrates the potential of SPHK inhibitors in combination with venetoclax as a promising treatment option for CLL patients by reducing the activation of CLL cells and the generation of venetoclax resistance induced by autologous activated T cells from CLL patients. [Read the Full Post]